Back in July the SP was 50p and rising. The OO, directors sells, Calculus sells etc are what spooked the market and dropped the SP to below 30p. Now all those doubt’s can be dismissed. Even if you consider the previous 50p level to have been hyped at the time, it’s not any more it’s proven fact RNS. Given since Moditope news and these results trading below the 50p mark is somewhat strange IMO
Will happen soon.
I think there could be RNSs flying all over the place about lots more than that. Just reread it again, crikey its good
inanaco's £1 price target
Much has been made of inanaco's suggestion that these shares should be trading at around £1. I have to say that I agree with him. They should be. Given the spectacular results of the SCIB1 ImmunoBody vaccine to date and its likely value to the industry of around 1 billion dollars and the rest of Scancell's IP (which is worth much much more) these shares should now be trading close to Navid Malik's target of 127.89 pence. I wouldn't like to predict the share price going forward but hopefully, given the increased exposure to Scancell that the recent SCIB1 results have given the investment community, we will see these shares approaching inanaco's target in the not too distant future.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.